TxBench: 113 evaluations test whether AI agents can drive ASO/siRNA drug discovery
kenbwork · x · 2026-09-10
TxBench-Oligonucleotide Discovery is a new benchmark testing whether AI agents can make scientific decisions across ASO and siRNA therapeutic discovery.
- 113 evaluations span ten stages across 21 discovery programs: target feasibility, sequence design, chemistry selection, screening, potency, off-target profiling, phenotype rescue, preclinical safety, and in vivo pharmacology
- The core challenge: interpreting efficacy alongside specificity, toxicity, and drug exposure — sequence, chemical modifications, and delivery all change how an experimental result should inform the next decision
- Example: the same off-target effect may reflect sequence-dependent silencing or a chemistry-driven effect unrelated to hybridization
More from Research
- CoopEval: a framework for comparing cooperation mechanisms in multi-agent systems — conitzer · 2026-09-10
- Open Yap 1K: 1,000 hours of natural two-speaker conversations, free for commercial use — realmrfakename · 2026-09-10
- Hank Yang: AI Excels at Well-Defined Problems, So the Real Skill Is Defining New Ones — hankyang94 · 2026-09-10
- Jacobian conjecture drama: Anthropic's Alpoge responds to leaked BGV paper concerns — suchenzang · 2026-09-10
- NNsight 0.8 pre-release ships faster engine, MoE and near-native vLLM support — davidbau · 2026-09-10
- ECCV talk outlines three pillars for embodied AI: motion prediction, evidence, streaming — CSProfKGD · 2026-09-10